

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/599,707
Filing Date	October 5, 2006
First Named Inventor	Lyn Howard Jones
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	PC32041A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	AA	6,933,312	08-23-2005	Agouron Pharmaceuticals, Inc.	
	AB	10/657,033	09-05-2003	Pfizer Limited	
	AC	6,586,430	07-01-2003	Pfizer, Inc.	
	AD	2004/122064	06-24-2004	Glaxo Smith Kline	
	AE	3,303,200	02-07-1967	American Home Products Corporation	
	AF	6,518,293	02-11-2003	Hoffmann-LaRoche, Inc.	
	AG	6,833,364	12-21-2004	Bayer HealthCare AG	
	AH	6,518,293	02-11-2003	Hoffmann-LaRoche, Inc.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AI	GB223234	06-04-03	Pfizer Limited		
	AJ	WO 91/11172	08-08-1991	The University of Kansas		
	AK	WO 94/02518	02-03-1994	The University of Kansas		
	AL	WO 98/55148	12-10-1998	Janssen Pharmaceutica		
	AM	WO 02/04424 A1	01-17-2002	Pfizer Limited		
	AN	WO 2004/031178	04-15-2004	Pfizer Limited		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designator number (optional). <sup>1</sup>See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 609.04. <sup>2</sup>State Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 (if possible). <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20531. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send fee Communications for Patents, P.O. Box 1480, Alexandria, VA 22303-1480.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/599,707
Filing Date	October 5, 2006
First Named Inventor	Lyn Howard Jones
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	PC32041A

AO	WO 02/34745	05/02/2002	Anormed Inc.		
AP	GB223232	10/07/2002	Pfizer Limited		
AQ	WO 02/085860	10/31/2002	Jones, et al		
AR	WO 2006/072833	07-13-2006	Pfizer Limited		
AS	WO 2006/067587	06-29-2006	Pfizer Limited		
AT	WO 2004/031156	04-15-2004	Pfizer Limited		
AU	EP 0 786 455	07-30-1997	Shionogi & Co., Ltd.		
AV	WO 02/30907 A1	04-18-2002	F. Hoffmann-La Roche		
AW	WO 02/02524	01-10-2002	F. Hoffmann-La Roche		
AX	WO 02/100853	12-19-2002	F. Hoffmann-La Roche		
AY	WO 02/42279	05-30-2002	F. Hoffmann-La Roche	Derwent Abstract Enclosed	
AZ	WO 00/06569	02-10-2000	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BA	WO 98/16507	04-23-1998	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BB	WO 00/21954	04-20-2000	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BC	WO 02/42300	05-30-2002	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BD	WO 02/42302	05-30-2002	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BE	WO 02/42301	05-30-2002	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BF	DE 198 34 047 A	02-03-2000	Bayer AG	Derwent Abstract Enclosed	
BG	WO 00/06567	02-10-2000	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	
BH	WO 98/23619	06-04-1998	Bayer Aktiengesellschaft	Derwent Abstract Enclosed	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with rest communication to applicant. Applicant's unique citation designation number (optional). See Kindle Codes of USPTO Patent Documents at www.uspto.gov or MPEP 600.04. \*Date Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the publication of the year of the signs of the Japanese must precede the serial number of the patent document. \*Kinded document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 (if possible). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20531. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send fee Communications for Priority, P.O. Box 1480, Alexandria, VA 22303 1480.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/599,707
Filing Date	October 5, 2006
First Named Inventor	Lyn Howard Jones
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	PC32041A

BI	WO 99/54296	10-28-1999	Shionogi & Co.		
BJ	WO 2004/024147	03-25-2004	Pfizer Limited		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the firm (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BK	BERGE, et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> , 1977, 1-19, vol. 66, no. 1.		
BL	CHAN, J., et al., "Novel Benzophenones as Non-nucleoside Reverse Transcriptase Inhibitors Of HIV-1," <i>Journal of Medicinal Chemistry</i> , 2004, 1175-1182, vol. 47.		
BM	CLERCQ, DE, E., "New Developments In Anti-HIV Chemotherapy," <i>Current Medicinal Chemistry</i> , 2001, 1543-1572, vol. 8, no. 13.		
BN	FERRIS, R., et al., "Antiviral Activity Of GW678248, A Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor," <i>Antimicrobial Agents And Chemotherapy</i> , 2005, 4046-4051, vol. 49.		
BO	GENIN, M. et al., "Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus The Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives," <i>Journal of Medicinal Chemistry</i> , 2000, 1034-1040, vol. 43.		
BP	HAJIMORAD, et al., "Some Observations On The Binding Properties Of Alfalfa Mosaic Virus To Polystyrene And Its Significance To Indirect ELISA," <i>Archives of Virology</i> , 1991, 219-235, vol. 117.		
BQ	OHKAWA, T., et al., "Structural Determination Of Metabolites Of S-1153, A New, Potent, Non-Nucleoside, Anti-HIV Agent In Rath Liver Microsomes," <i>Xenobiotica</i> , 1998, 877-886, vol. 28, no. 9.		
BR	STANOVNIC, et al., <i>Science of Synthesis</i> , 2002, 15-225, vol. 12.		
B2	Topics in Chemistry, Chapter 31, 306-316, (Not Available)		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conference with MPEP 609. Draw line through citation if not in conference and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 600.04. \*State Office that issued the document, by the two-letter code (WFO Standard 51.3) \*For Japanese patent documents, the publication of the year of the origin of the document must precede the serial number of the patent document. \*Kinded document by the appropriate symbols as indicated on the document under WFO Standard 57. 16 (if possible) \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20531. DO NOT SEND PAPER OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1480, Alexandria, VA 22303-1480.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/599,707
Filing Date	October 5, 2006
First Named Inventor	Lyn Howard Jones
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	PC32041A

BT	WAHHAB, A., et al., "Imidazole Based Non-peptide Angiotensin II Receptor Antagonists: Investigation Of The Effect Of The Orientation Of The Imidazole Ring On Biological Activity," <i>Arzneimittel-Forschung</i> , 1993, 1157-1168, vol. 43, no. 11.	
BU	WYATT, P., et al., "Benzophenone Derivatives: A Novel Series Of Potent And Selective Inhibitors Of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>Journal Of Medicinal Chemistry, American Chemical Society</i> , 1995, 1657-1665, vol. 38, no. 10.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). \*See Kindle Codes of USPTO Patent Documents at www.uspto.gov or MPEP 609.04. \*Date Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the signs of the Emperor must precede the serial number of the patent document. \*Kinded document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 (if possible). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20531. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send fee Communications for Patents, P.O. Box 1480, Alexandria, VA 22303 1480.